Daniel Jelovcan
Daniel Jelovcan is an analyst at Zürcher Kantonalbank (ZKB), specializing in the medical technology sector. He provides insights into the performance of companies like Sonova, highlighting the challenges they face in the U.S. market, particularly regarding sales of hearing aids amidst economic uncertainties and budget cuts affecting government contracts.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Switzerland | 1 | 8.00 | 0.09% | +0% | 8,654,622 | 7,911 | $700,000 | 640$ |
| Totals | 1 | 8,654,622 | 7,911 | $700,000 | 640$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Switzerland:
Daniel Jelovcan, a Medtech expert at Zürcher Kantonalbank, is convinced of the products and developments that Sonova has recently launched.
8
Switzerland:
Daniel Jelovcan, an analyst at ZKB, explains Sonova's market share performance in the VA sector.
6
Switzerland:
Daniel Jelovcan noted that Tecan needs fresh leadership and welcomed the CEO change.
7
Switzerland:
Daniel Jelovcan is an analyst at Zürcher Kantonalbank who observes Medacta since its IPO.
8
Switzerland:
Daniel Jelovcan, an analyst at Zürcher Kantonalbank, notes the decline in hearing aid sales in the US.
5